Navigation Links
Einstein College of Medicine given $6.7 million to study congenital heart defect genetics
Date:10/11/2011

October 11, 2011 (Bronx, NY) The Eunice Kennedy Shriver National Institute of Child Health & Human Development, part of the National Institutes of Health, has awarded researchers at Albert Einstein College of Medicine of Yeshiva University and collaborators at the Children's Hospital of Philadelphia (CHOP) a five-year, $6.7 million grant to study the genetics of both rare and common congenital heart abnormalities known as conotruncal defects (CTDs).

CTDs account for more than one-third of all heart defects. They can involve a faulty connection between the heart's chambers or an abnormality affecting a major blood vessel leaving the heart. Some of the more common CTDs include ventricular septal defects and tetralogy of Fallot.

"We hope that this project will greatly expand our understanding of the genetic basis of CTDs and lead to novel therapies and preventive strategies for these defects," said principal investigator Bernice Morrow, Ph.D., director of translational genetics, professor of genetics and the Sidney L. and Miriam K. Olson Chair in Cardiology at Einstein. Dr. Morrow has appointments in obstetrics & gynecology and women's health and pediatrics.

The first part of Dr. Morrow's study will examine CTDs occurring in patients with velo-cardio-facial/DiGeorge syndrome, also called 22q11.2 deletion syndrome (22q11DS). The syndrome is caused by the deletion of a small piece of chromosome 22 known as q11.2. This deletion, present in about one in every 4,000 live births, can cause a variety of developmental abnormalities in addition to CTDs, including immune deficiencies, mild craniofacial deformities and behavioral or intellectual disabilities. There is no cure for the disorder. Dr. Morrow and collaborators at CHOP have formed an International 22q11.2 Consortium to greatly expand the number o
'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Einstein researchers develop a new way to study how breast cancer spreads
2. Einstein researchers develop technique to count messages made by single genes
3. Einstein scientists receive $10 million NIH grant
4. Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine
5. Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time
6. NIH funds research center for womens reproductive health at Einstein
7. Einstein researchers devise a fast and sensitive way to detect ricin
8. Einstein scientists move closer to a safer anthrax vaccine
9. Einstein receives high-risk/high-reward cancer research funding
10. Einstein to develop anti-HIV drug delivery system
11. Einstein researchers discover 2 new ways to kill TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... us that we inherit certain traits from our parents ... how these genes play out by taking certain drugs ... exactly what a team of researchers at the Boston ... research of epigenetics research. , Epigenetics regulates gene ... and histone proteins, which prevent permanent mutations or alterations ...
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
(Date:9/16/2014)... diameter chunk of rock hit the Yukatan peninsula near the ... of 100 teratons of TNT. It left a crater more ... earthquakes and volcanism are widely accepted to have wiped out ... mammals. But what happened to the plants on which the ... the University of Arizona reveals that the meteorite impact that ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... The world,s leading conservation organizations have joined together to fight ... gorilla ( Gorilla beringei graueri ). Found only in ... of Congo (DRC), Grauer,s gorilla is not only the largest ... in the world. With their entire range consumed in ...
... and walked on two legs is considered to be one of ... to the far ends of the earth and the wonderful ... walk the way we walk. In the latest such search, ... have taken a closer look at bipedal kangaroos and wallabies and ...
... PA, March 13, 2013 Many Canadians are concerned ... sodium intake through a variety of measures, including lowering ... a national survey. The top barriers to limiting sodium ... processed foods and lower sodium restaurant menu options. ...
Cached Biology News:Gorillas caught in the crossfire in the DRC 2Gorillas caught in the crossfire in the DRC 3It's all in the way we move 2Canadians support interventions to reduce dietary salt 2
(Date:9/17/2014)... -- BioClinica®, Inc., a leading provider of outsourced clinical ... its experts are speaking at the 20th Annual ... held September 28 to October 1 in ... the innovative Compass technology, a risk-based monitoring ... earlier this year, is up for the Technology ...
(Date:9/17/2014)... Alternative Fuels Americas, Inc. (AFAI) announced today that ... Vehicle in partnership with Jatro Greentech, Inc., a ... SPV shall be called AFAI Jatro Green Ethiopia and will ... The SPV shall pursue Jatropha planting and biofuels production projects ... . "Although we have experienced great ...
(Date:9/17/2014)... Beckman Coulter , a global ... has renewed its agreement with Personify for ... agreement, Personify will continue to streamline the Beckman Coulter ... analytics, including time-to-fill, time-to-source and a deep reduction to ... Personify was based on the success of our partnership ...
(Date:9/17/2014)... 2014 The Alliance for ... multi-stakeholder non-profit collaborative building a global system to ... today announced Phase 3 of its Site Accreditation ... Amir H. Kalali, Vice-President, Global Head, Neuroscience Center ... Compliance and Quality Integration (CQI) Consulting will lead ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4
... Merrimack Pharmaceuticals, Inc. announced today that it ... therapeutic consisting of a mixture of three human ... irinotecan, at the 14th World Conference on Lung ... in Amsterdam, The Netherlands. (Logo: ...
... Dendreon Corporation (Nasdaq: DNDN ) today ... approved its Los Angeles cancer immunotherapy manufacturing facility, allowing ... PROVENGE ® (sipuleucel-T) across the U.S. to help ... symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.   ...
... Branch Fund: A Thisbe and Noah Scott Legacy, an ... announced its first funding award to Kevin Eggan, Ph.D., ... Harvard University.  The award will support Dr. Eggan,s ongoing ... affect it.  Dr. Eggan is a leading researcher in ...
Cached Biology Technology:Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 3FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 4The Olive Branch Fund Announces Funding Award to Harvard Researcher 2
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
... Inhibitor is a recombinant protein that has been ... in the preparation of cDNA by reverse transcription, ... protein synthesis. RNA Safe Inhibitor tightly binds RNases ... range of eukaryotic RNases such as RNase A, ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: